Interleukin 18 (IL18) is a proinflammatory cytokine whose levels are increased in the subclinical stage of insulin-dependent (type I) diabetes mellitus. Previous case-control studies have reported associations between IL18 À607C4A and À137G4C promoter polymorphisms and type I diabetes. We performed case-control and family-based association studies employing Pyrosequencing to assess if these IL18 polymorphisms are also associated with the development of type I diabetes in the Northern Ireland population. The w 2 analysis of genotype and allele frequencies for the IL18 polymorphisms in cases (n ¼ 433) vs controls (n ¼ 426) revealed no significant differences (P40.05). Assessment of allele transmission distortion from informative parents to affected offspring also failed to confirm previously reported associations. Stratification of these analyses for age-at-onset and HLA-DR type did not reveal any significance associations. In conclusion, our data do not support the strong positive associations of IL18 promoter polymorphisms with type I diabetes reported in previous smaller studies.
Introduction
Insulin-dependent (type I) diabetes is an autoimmune disease mediated by Th1 lymphocytes resulting in T-cellmediated destruction of insulin-producing pancreatic b cells. [1] [2] [3] Increased levels of interleukin 18 (IL18) have been reported in individuals at high risk of developing type I diabetes. 4 IL18 is a proinflammatory cytokine secreted mainly by activated monocytes and macrophages. It is involved in the regulation of the innate and acquired immune response and plays a key role in autoimmune, inflammatory and infectious diseases. 5 Acting in synergy with IL12, IL18 promotes development of the Th1 lymphocyte response by induction of ginterferon (IFN-g). It also modulates activity of T lymphocytes and NK cells, induces TNFa and IL1 production by macrophages and induces nitric oxide production in the area of chronic inflammation. 5, 6 The active stage of autoimmune diabetes in the NOD mouse is associated with increased IL18 mRNA production by macrophages followed by increased IFN-g levels. 7, 8 Functional IL18 is also produced by primary pancreatic mouse b cells and participates in destructive insulitis. 9, 10 In contrast, systemic administration of exogenous IL18 to NOD mice suppresses the development of diabetes by counter regulation of Th1-dependent destructive insulitis.
11
IL18 is therefore an excellent candidate gene for type I diabetes. A previous study in Poland has reported an association between both IL18 -607C4A and -137G4C promoter polymorphisms and type I diabetes. 12 While a recent Japanese study confirmed the protective effect of the À607A allele, it failed to find an association with the À137 polymorphism. 13 Both polymorphisms impact on IL18 gene activity by altering transcription factor binding. A change from C to A at position À607 disrupts a potential cAMP-responsive element-binding proteinbinding site, while a change at position À137 from G to C changes the H4TF-1 nuclear factor-binding site to a binding site for an unknown factor found in the GM-CSF promoter. 14 The aim of this study was to investigate previous associations of IL18 promoter polymorphisms with type I diabetes in the Northern Ireland population, employing a combination of case-control and family-based association analyses. For the case-control study, 433 probands were recruited; parents and grandparents of each proband were born in Northern Ireland. DNA from both parents was also available for 285 of the 433 probands. These trios were employed for the family-based association study. The diagnosis of type I diabetes was based upon elevated plasma glucose levels above diagnostic threshold values defined for type I diabetes and an absolute dependency on insulin. Cases with type I diabetes secondary to another condition were excluded. Probands were derived from a Northern Ireland register of newly diagnosed early onset patients with type I diabetes, diagnosed before their 15th birthday. 15, 16 Controls (n ¼ 426, mean age 13.5 yrs) were derived from the Young Heart's 2000 Study collection; a group of unrelated healthy children selected from a random sample of Northern Ireland schools. 17 
Results and discussion
The distribution of IL18 À607C4A and À137G4C genotypes in cases and controls were in the HardyWeinberg equilibrium. Genotype and allele frequencies for IL18 promoter polymorphisms did not differ significantly in cases compared to controls ( Table 1 ). The IL18 À607A allele was decreased in cases (36.5%) compared to controls (40.8%); however, it failed to reach 19 the two IL18 loci were found to be in strong linkage disequilibrium in both cases (D 0 ¼ 0.992) and controls (D 0 ¼ 1.000). Distributions of estimated IL18 À137/À607 haplotype frequencies in cases and controls are shown in Table 2 . Differences in the haplotype frequencies in the Northern Ireland cases compared to controls did not attain significance (P ¼ 0.18).
The transmission disequilibrium test (TDT) was performed for both IL18 polymorphisms on 285 trios (cases from case-control study and parents where available). No significant distortion in allele transmissions was observed for the IL18 polymorphisms in informative families (Table 3) . Furthermore, stratification for the age at diagnosis of diabetes (o5 and X5 years) and for the case's HLA-DR risk group (DR3/DR4 heterozygotes, other carriers of DR3, other carriers of DR4) revealed no statistically significant differences in case-control and TDT studies (data not shown).
The IL18 À137C allele has been reported to be significantly increased in a Polish 12 type I diabetic population; however, this was not replicated here or in a recent Japanese study. 13 We also failed to confirm previous findings in Poland and Japan, suggesting that the IL18 À607AA genotype frequency is significantly decreased in cases vs controls, although we did find some evidence that the À607A allele was less common in cases. This slight deficit of À607A alleles among our cases was not supported, however, by analysis of transmissions of alleles from heterozygous parents to affected offspring in 285 case trios. Furthermore, stratification of our data according to the age at diagnosis of diabetes (o5 and X5 years) and HLA-DR risk group (DR3/DR4 heterozygotes, other carriers of DR3, other carriers of DR4) revealed no statistically significant differences between groups.
In contrast to our data, significant deviation from the Hardy-Weinberg equilibrium is apparent in the genotype distributions of cases in the Japanese 13 study and in the genotype distributions of both cases and controls in the Polish 12 study. Although a significant interaction between IL18 À137G/À607C and CTLA4 49GG was reported by Ide et al, 13 the data they present are not consistent with the P-value given by the authors (P ¼ 0.016). The correct test shows little evidence to support a gene-gene interaction (w 2 ¼ 1.19, df ¼ 1; P ¼ 0.27). Moreover, our own data failed to reveal any evidence of an interaction between the IL18 promoter polymorphisms examined and CTLA4 49A4G (data not shown). 20 and compared between cases and controls with FastEHPlus, which calculates a likelihood ratio w 2 -test and assesses its significance by referring it to the distribution of test statistics obtained from random permutations of the case-control labels. 21 Our study is the largest case-control study and the first family-based association study to date to investigate the role of IL18 À137 and À607 promoter polymorphisms in type I diabetes. The sample sizes in our study (433 cases, 426 controls) were larger than the Polish 12 (201 cases, 194 controls) and Japanese 13 (116 cases, 114 controls) studies combined. Indeed, our case-control data was of sufficient size to have 90% power to detect as significant (Po0.05; two-tailed) an allele-wise increase in risk of 40% (odds ratio of 1.40) for either the À137C allele, for which the Polish study reported an odds ratio of 1.60 (95% CI: 1.17, 2.19), and 80% power to detect a 25% decrease in risk (odds ratio of 0.75) for the À607A allele, for which the Japanese study found an odds ratio of 0.71 (95% CI: 0.48, 1.03). Our findings suggest that if an association between these polymorphisms and type I diabetes exists, it is weaker in the Northern Ireland population where we found the À137C allele to have an odds ratio of 0.89 (95% CI: 0.71, 1.10) and the À607A allele to have an odds ratio of 0.83 (95% CI: 0.68, 1.02).
Failure to replicate candidate gene associations can result from small sample sizes, study design or genetic heterogeneity. [23] [24] [25] Difficulties associated with controls can, however, be overcome by the use of family member controls as employed in this study through the use of TDT analysis. In our study, the age at diagnosis was under 15 years, whereas in the Polish 12 and Japanese 13 studies the age at diagnosis of the cases was under 30 years. It is also noteworthy that IL18 genotype frequencies differ between populations. The IL18 À607AA genotype is extremely rare in the Polish population, occurring in only 5.7% of controls, and absent in cases. 12 In contrast, in Japan, 13 the À607AA genotype occurs in 26.3% of controls, while in the present study and other northern European 14 studies 14-16% has been recorded. This variation in allele and genotype frequency is also reflected in IL18 haplotype frequencies. The haplotype frequencies for the Northern Ireland population are similar to those reported for controls from Poland 12 and Sweden, 14 but different from those reported in healthy Japanese 13 individuals (Table 2 ). In conclusion, we failed to identify any significant association between IL18 promoter polymorphisms and type I diabetes employing both case-control and familybased studies. IL18 À607C4A and 137G4C polymorphisms do not play a major role in the development of type I diabetes in the Northern Ireland population. Assessment of allele transmission distortion from the expected 50 : 50 transmission from informative parents to offspring was performed using the transmission disequilibrium test.
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